Skip to main content

News

Dr Pakeeran Siriratnam

 

People may recall completing a survey way back in mid-2022 when researcher Dr Pakeeran Siriratnam was keen to understand more about our Covid experiences. He was delighted when 229 people successfully responded. After much time and effort Dr Sisriratnam’s paper was published in a prominent journal just prior to Christmas. He has responded to the MAA request for feedback.

PBAC Submission - Time for your Submission

A big thank you to everyone who attended and participated in ou

Webinar Registrations Closing

Don't hesitate for one more minute! Register 

Webinar Register Here

It is a new year and we have a once in a generation opportunity for new treatments for Myasthenia Gravi

PBAC Submission Rozanolixizumab

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda! 

PBAC Submission Efgartigimod

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda

PBAC Submission Ravulizumab and Zilucoplan

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda!

The MAA has partnered with the University of the Sunshine Coast to conduct research on Myasthenia Gravis and people’s ability to work. The research team is led by Dr. Michele Verdonck.

Subscribe to MGAQ News

MessaGes Mailing List

Enter your details below to receive our monthly MessaGes Newsletter and upcoming News and Events directly to your Email inbox.